As Tirzepatide later demonstrated substantial weight-loss benefits in non-diabetic, overweight individuals (reinforced by both the SURPASS and SURMOUNT trials), Eli Lilly introduced Zepbound as a separate product approved specifically for weight loss and obesity-related conditions, including sleep apnea
I-BET151 (a selective inhibitor of BET) can reduce joint inflammation and bone loss by blocking MMP-1, MMP-3, IL-6, and IL-8 production in RA FLS (190, 306)
An ongoing phase 2 trial (NCT04867616) enrolling 421 participants with prodromal or mild AD is investigating the safety, tolerability, and efficacy of bepranemab
These findings suggest that high GSH intake correlates with poorer prognosis in breast cancer patients who underwent adjuvant chemotherapy
In general, highest (poly)peptide solubilities were obtained in glycerol monocaprylocaprate:caprylic acid in a ratio of 1:4 (m/m)
CHS continues to underperform its publicly traded peers as an operator